Wake Forest University Health Sciences: Oligodendroglioma trials

The registry lists 11 Oligodendroglioma studies with Wake Forest University Health Sciences as lead sponsor. 0 are open to participants now and 2 have results posted.

Early Phase 1 1Phase 1 1Phase 2 3Phase 3 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain TumorsCompletedNCT01032200Phase 2Results posted
• Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain TumorsCompletedNCT00369785Phase 3Results posted
• Social Determinants of Health in Glioblastoma PopulationCompletedNCT03900689
• Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain MetastasesTerminatedNCT03796273Early Phase 1
• Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain TumorsCompletedNCT02747407
• Yoga Therapy in Treating Patients With Malignant Brain TumorsTerminatedNCT01234805Not applicable
• Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant GliomaTerminatedNCT01103375Phase 1
• Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain TumorsCompletedNCT00499798
• Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00079092Phase 2
• Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain TumorCompletedNCT00070161Phase 2
• Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain TumorsTerminatedNCT00031798Phase 3